Moleculin Biotech Inc (MBRX) concluded trading on Thursday at a closing price of $1.27, with 103.31 million shares of worth about $131.21 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -45.96% during that period and on February 13, 2025 the price saw a gain of about 202.38%. Currently the company’s common shares owned by public are about 4.16M shares, out of which, 4.03M shares are available for trading.
Stock saw a price change of 51.12% in past 5 days and over the past one month there was a price change of -32.09%. Year-to-date (YTD), MBRX shares are showing a performance of -25.29% which decreased to -83.62% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.40 but also hit the highest price of $10.35 during that period. The average intraday trading volume for Moleculin Biotech Inc shares is 158.53K. The stock is currently trading -4.96% below its 20-day simple moving average (SMA20), while that difference is down -27.61% for SMA50 and it goes to -55.98% lower than SMA200.
Moleculin Biotech Inc (NASDAQ: MBRX) currently have 4.16M outstanding shares and institutions hold larger chunk of about 10.24% of that.
The stock has a current market capitalization of $5.29M and its 3Y-monthly beta is at 1.98. It has posted earnings per share of -$11.69 in the same period. It has Quick Ratio of 2.08 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MBRX, volatility over the week remained 126.17% while standing at 38.77% over the month.
Analysts are in expectations that Moleculin Biotech Inc (MBRX) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is -5.28 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 49.80% while it is estimated to increase by 47.26% in next year. EPS is likely to grow at an annualized rate of 36.38% for next 5-years, compared to annual growth of 18.25% made by the stock over the past 5-years.
Coverage by Oppenheimer stated Moleculin Biotech Inc (MBRX) stock as an Outperform in their note to investors on July 18, 2022, suggesting a price target of $14 for the stock.
